7 completed, 1 active not recruiting, 1 withdrawn. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Stage III Soft Tissue Sarcoma AJCC v7: new trials by email Literature Review of Stage III Soft Tissue Sarcoma AJCC v7 trials Research Report on Stage III Soft Tissue Sarcoma AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Biopsy, Laboratory Biomarker Analysis, Trabectedin - Myxoid Liposarcoma, Round Cell Liposarcoma | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2018-06-19 | 2019-09-10 | |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 164 | 2015-08-13 | 2023-10-17 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
Sarcoma (9) · Glioma (4) · Histiocytoma, Malignant Fibrous (4) · Liposarcoma (4) · Central Nervous System Neoplasms (3) · Dermatofibrosarcoma (3) · Ependymoma (3) · Hepatoblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Lymphoma, Non-Hodgkin (3) · Medulloblastoma (3) · Neuroblastoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Neurofibrosarcoma (3) · Osteosarcoma (3)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Connective and Soft Tissue (9) · Neoplasms, Connective Tissue (7) · Neoplasms, Nerve Tissue (7) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Neoplasms by Site (5) · Neoplasms, Adipose Tissue (5) · Neoplasms, Muscle Tissue (5) · Urogenital Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)
Biopsy (2) · Doxorubicin (2) · LY3023414 (2) · Magnetic Resonance Spectroscopy (2) · Phantoms, Imaging (2) · Specimen Handling (2) · X-Rays (2) · tazemetostat (2) · CTLA-4 Antigen (1) · Depsipeptides (1) · Ifosfamide (1) · Ipilimumab (1) · Lactones (1) · MLN 8237 (1) · Nivolumab (1)
National Cancer Institute (NCI) (7) · Fred Hutchinson Cancer Center (1) · OHSU Knight Cancer Institute (1)
United States (9) · Puerto Rico (4) · Canada (3) · Australia (1)
Aaron R Weiss (1) · Donald W Parsons (1) · Lara E Davis (1) · Mark Dickson (1) · Roisin M Connolly (1) · Sandra P D'Angelo (1) · Seth Pollack (1) · Susan N Chi (1) · Theodore W Laetsch (1)
PMID 27502708, PMID 29370992, PMID 31401903, PMID 32702309, PMID 32827353, PMID 33591402, PMID 34515544, PMID 35353553, PMID 37523624, PMID 39343511, PMID 39863139, PMID 41166674, PMID 42686334
U10CA180886 (4), U10CA180821 (2), P30CA015704 (1), U01CA062505 (1), U01CA069912 (1), U01CA070095 (1), U01CA132123 (1), U10CA031946 (1), U10CA098543 (1), U10CA180830 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186691 (1)